Abstract:Belatacept, a high-affinity variant of CTLA4-Ig, is a recently approved immunosuppressive agent for the prevention of acute rejection. It functions as a potent antagonist of the CD28-B7 interactions, thereby inhibiting T cell co-stimulation and activation. Experimental data involving the transient use of CTLA4-Ig to induce allograft tolerance have shaped the current paradigm that CTLA-4Ig is ineffective at inhibiting memory T cell responses, and by extension T-dependent alloantibody responses. This resistance is explained by the acquisition of additional activation-induced costimulatory molecules by memory T cells. We noted that the efficacy of CTLA4-Ig as a continuously administered drug for controlling rejection in sensitized recipients has not been investigated. Here we report on the efficacy of CTLA4-Ig in preventing acute rejection in sensitized C57BL/6 recipients that had received BALB/c spleen cell transfusion 3-6 months previously. We set up four experimental groups. Group 1 (N=5): sensitized mice with HTX and CTLA4-Ig treated (Day -2, Day 0, Day2, then weekly (1 mg/dose) Group 2 (N=3): sensitized mice with HTX and no CTLA4-Ig, Group 3: (N=10) naive mice with HTX and CTLA4-Ig treated, Group 4 (N=10): naive mice with HTX and no CTLA4-Ig. In the untreated Groups 2 & 4, allografts were rejected within 7 days post-transplantation, whereas in Group 3 of naive mice receiving CTLA4-Ig, all the grafts survived long-term (>90 days). In Group 1 of sensitized recipients receiving CTLA4-Ig, the allografts survived for 42, 42, 49, >90, >90 days. The pre-transplant donor-specific antibody (DSA) titers in the recipients that went on to reject their graft was significantly higher compared to those that accepted their grafts. Furthermore, DSA titers increased post-transplantation in the recipients that went on to reject their allografts, whereas DSA titers decreased in those that accepted their grafts. In conclusion, these observations illustrate the efficacy of CTLA-4Ig treatment at controlling rejection in sensitized recipients, and underscore the barrier pre-transplantation DSA poses to long-term graft acceptance. This experimental model also provides a unique opportunity for testing if DSA promotes antibody-mediated rejection or alloreactive memory T cell priming and T cell-mediated rejection in CTLA4-Ig treated recipients, and for identifying therapies that promote long-term graft survival in sensitized recipients.

Anti-ICAM-1 Antibody and CTLA-4Ig Synergistically Enhance Immature Dendritic Cells to Induce Donor-Specific Immune Tolerance in Vivo

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin.

Combined Treatment of Allograft Recipients with CTLA-4 Ig and Anti-Icam-1 Mab Plus Transfusion of Donor-Specific DC Progenitors

Cardiac Allograft Tolerance Induced by Isogeneic CD4+CD25+ Regulatory T Cells.

TGF-beta(1) gene modified immature dendritic cells exhibit enhanced tolerogenicity but induce allograft fibrosis in vivo.

Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with FTY720 prolongs the survival of cardiac retransplantation allografts in a mouse model

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

Pretreatment of Donor Dendritic Cells with NBD-peptide Prolongs Mouse Cardiac Allograft Survival

Effective Induction of Immune Tolerance by Portal Venous Infusion with IL-10 Gene-Modified Immature Dendritic Cells Leading to Prolongation of Allograft Survival

Marked Prolongation of Cardiac Allograft Survival by Dendritic Cells Genetically Engineered with Nf-Kappa B Oligodeoxyribonucleotide Decoys and Adenoviral Vectors Encoding Ctla4-Ig

Induction of mixed chimerism and cardiac transplantation tolerance by CTLA-4 Ig adenovirus gene therapy combined with infusion of donor cells in allogeneic rats

Tolerance Induction by Exosomes from Immature Dendritic Cells and Rapamycin in a Mouse Cardiac Allograft Model.

Graft Protective and Intercellular Immunomodulatory Effects by Adoptive Transfer of an Agonistic Anti-BTLA mAb (3C10) Induced CD4+CD25+ Regulatory T Cells in Murine Cardiac Allograft Transplant Model

Alternative Immunomodulatory Strategies for Xenotransplantation: CD80/CD86-CTLA4 Pathway-Modified Immature Dendritic Cells Promote Xenograft Survival.

Adoptive Transfusion of Tolerance Dendritic Cells Prolongs the Survival of Cardiac Allograft: a Systematic Review of 44 Basic Studies in Mice

Inhibition of ICAM-1/LFA-1 interactions prevents B-cell-dependent anti-CD45RB-induced transplantation tolerance.

Generation of therapeutic dendritic cells and regulatory T cells for preventing allogeneic cardiac graft rejection.

IMMUNE MODULATION AND PREVENTION OF ALLOGENEIC GRAFT REJECTION BY THERAPEUTIC DENDRITIC CELLS:

SYNERGISTIC TOLERANCE BY ADOPTIVE TRANSFER OF TOLEROGENIC DENDRITIC CELLS AND T REGULATORY CELLS:

Blockade of γc signals in combination with donor-specific transfusion induces cardiac allograft acceptance in murine models